Abstract
The rapid development of genetic studies, not only in haemophilia but also in other congenital coagulopathies and platelet-related alterations, has been made possible by massive sequencing (e.g. next-generation sequencing or NGS), which allows a rapid and automatic analysis of the whole gene, simultaneous study of several genes and multiple individuals, detection of genetic variants and the possibility to create personalized panels [16]. The new technologies have also changed the way results are evaluated. Currently, our interest goes beyond the study of carriers, extending to the relationship between the mutation and the risk of developing an inhibitor and the latter's role in the classification of diseases [17]. There is also great interest in understanding the genotype/phenotype relationship, analytical discrepancies and variations in the response to treatment [18].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
